Editas Medicine (EDIT) Stock Chart & Stock Price History $2.65 +0.02 (+0.91%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Editas Medicine Stock Price Performance The Editas Medicine (EDIT) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 32.98%, with a year-to-date return of 108.98%. In the past month, the stock has decreased 3.84%, reflecting recent market activity. As of the latest close, Editas Medicine traded at $2.63 with a market cap of $236.49 million and volume of 1.47 million shares. Five years ago, the stock traded at $36.76, representing a 92.78% decrease over that period. At the time, it had a market cap of $2.31 billion and a volume of 556,902 shares. Receive EDIT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-12.41%1 Month Performance-3.84%3 Month Performance+61.83%Year-To-Date Performance+108.98%1 Year Performance-32.98%5 Year Performance-92.78% EDIT Stock Chart for Wednesday, August, 20, 2025 EDIT Chart by TradingView Editas Medicine Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/19/2025$2.73$2.63-3.66%$2.72$2.601.47 million shs$236.49 million08/18/2025$3.03$2.73-9.90%$3.08$2.731.84 million shs$245.48 million08/15/2025$2.96$3.03+2.36%$3.10$2.843.20 million shs$272.46 million08/14/2025$3.08$2.96-3.90%$3.11$2.892.27 million shs$247.78 million08/13/2025$2.29$3.08+34.50%$3.17$2.447.73 million shs$257.84 million08/12/2025$2.20$2.29+4.09%$2.33$2.181.29 million shs$191.70 million08/11/2025$2.21$2.20-0.45%$2.22$2.071.63 million shs$184.16 million08/08/2025$2.49$2.21-11.24%$2.52$2.202.26 million shs$185.00 million08/07/2025$2.53$2.49-1.58%$2.58$2.45873,793 shs$208.44 million08/06/2025$2.60$2.53-2.69%$2.63$2.471.16 million shs$217.65 million Get the Latest News and Ratings for EDIT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. 08/05/2025$2.56$2.60+1.56%$2.67$2.471.62 million shs$217.65 million08/04/2025$2.44$2.56+4.92%$2.61$2.441.28 million shs$214.30 million08/01/2025$2.51$2.44-2.79%$2.49$2.371.62 million shs$204.25 million07/31/2025$2.52$2.51-0.40%$2.58$2.402.13 million shs$210.12 million07/30/2025$2.59$2.52-2.70%$2.72$2.502.31 million shs$210.95 million07/29/2025$2.96$2.59-12.50%$2.99$2.553.80 million shs$216.81 million07/28/2025$3.15$2.96-6.03%$3.19$2.941.80 million shs$247.79 million07/25/2025$3.26$3.15-3.37%$3.28$3.101.27 million shs$263.70 million07/24/2025$3.46$3.26-5.78%$3.58$3.182.66 million shs$272.90 million07/23/2025$3.36$3.46+2.98%$3.54$3.282.46 million shs$289.64 million07/22/2025$3.15$3.36+6.67%$3.42$3.032.60 million shs$281.28 million07/21/2025$2.76$3.15+14.13%$3.39$2.795.76 million shs$263.69 million Related Companies Beam Therapeutics Stock Chart CRISPR Therapeutics Stock Chart Intellia Therapeutics Stock Chart Nurix Therapeutics Stock Chart Tango Therapeutics Stock Chart Stoke Therapeutics Stock Chart Phathom Pharmaceuticals Stock Chart Amylyx Pharmaceuticals Stock Chart BGM Group Stock Chart Gyre Therapeutics Stock Chart Receive EDIT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:EDIT) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWinning the AI WarWhat’s really driving the trade wars, reshoring, and sweeping executive orders? According to Porter Stansberry...Porter & Company | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access